Pharmaceuticals
Our global Pharmaceuticals portfolio includes more than 45 key marketed products, many of which are leaders in their respective therapeutic areas. We have received 17 new pharmaceutical product approvals in the US since 2000, the most of any pharmaceutical company.
Key pharmaceutical products marketed by Novartis are listed below by therapeutic area.
Click on the product link where available to display complete product information. Please note that some product links are intended for US residents only.
Most popular products
Diovan HCT/Co-Diovan (valsartan and hydrochlorothiazide)
Hypertension
Visit www.diovan.com (US residents only)
Gleevec/Glivec (imatinib mesylate/imatinib)
Certain forms of leukemia, gastrointestinal stromal (GIST) tumors and various rare cancers
Visit www.glivec.com
Visit www.gleevec.com (US residents only)
Lamisil (terbinafine)
Antifungal agent
Visit www.lamisil.com (US residents only)
Zometa (zoledronic acid)
Cancers that have spread (or "metastasized") to the bones from solid tumors
Visit www.zometa.com
Visit www.us.zometa.com (US residents only)
Pharmaceuticals business at Novartis
Novartis discovers and develops innovative medicines with improved efficacy and fewer side-effects.
About Novartis
We provide medicines to treat and prevent diseases, ease suffering and improve quality of life.
Fast facts
Our headquarters is based in Basel, Switzerland